PMV Pharmaceuticals (PMVP) Competitors

$1.27 -0.04 (-2.67%)

As of 03:25 PM Eastern

PMVP vs. PRLD, EDIT, ALXO, TRDA, and MGNX

Should you buy PMV Pharmaceuticals stock or one of its competitors? MarketBeat compares PMV Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PMV Pharmaceuticals include Prelude Therapeutics (PRLD), Editas Medicine (EDIT), ALX Oncology (ALXO), Entrada Therapeutics (TRDA), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry.

How does PMV Pharmaceuticals compare to Prelude Therapeutics?

PMV Pharmaceuticals (NASDAQ:PMVP) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

In the previous week, Prelude Therapeutics had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 2 mentions for Prelude Therapeutics and 0 mentions for PMV Pharmaceuticals. Prelude Therapeutics' average media sentiment score of 0.27 beat PMV Pharmaceuticals' score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PMV Pharmaceuticals	Neutral
Prelude Therapeutics	Neutral

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 79.7% of Prelude Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PMV Pharmaceuticals has higher earnings, but lower revenue than Prelude Therapeutics. Prelude Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Prelude Therapeutics	$12.14M	22.91	-$99.50M	-$1.00	N/A

PMV Pharmaceuticals has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

PMV Pharmaceuticals' return on equity of -68.98% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Prelude Therapeutics	N/A	-118.24%	-66.12%

PMV Pharmaceuticals presently has a consensus target price of $5.00, indicating a potential upside of 292.16%. Prelude Therapeutics has a consensus target price of $7.67, indicating a potential upside of 73.65%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe PMV Pharmaceuticals is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

PMV Pharmaceuticals beats Prelude Therapeutics on 9 of the 15 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Editas Medicine?

Editas Medicine (NASDAQ:EDIT) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.

Editas Medicine has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

71.9% of Editas Medicine shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 3.1% of Editas Medicine shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PMV Pharmaceuticals has lower revenue, but higher earnings than Editas Medicine. Editas Medicine is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52M	6.46	-$160.06M	-$1.23	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Editas Medicine presently has a consensus price target of $5.40, suggesting a potential upside of 101.87%. PMV Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 292.16%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Editas Medicine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

PMV Pharmaceuticals has a net margin of 0.00% compared to Editas Medicine's net margin of -281.59%. PMV Pharmaceuticals' return on equity of -68.98% beat Editas Medicine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

In the previous week, Editas Medicine had 2 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 2 mentions for Editas Medicine and 0 mentions for PMV Pharmaceuticals. Editas Medicine's average media sentiment score of 0.65 beat PMV Pharmaceuticals' score of 0.00 indicating that Editas Medicine is being referred to more favorably in the media.

Company	Overall Sentiment
Editas Medicine	Positive
PMV Pharmaceuticals	Neutral

Summary

PMV Pharmaceuticals beats Editas Medicine on 9 of the 16 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to ALX Oncology?

ALX Oncology (NASDAQ:ALXO) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

ALX Oncology presently has a consensus price target of $4.60, suggesting a potential upside of 132.91%. PMV Pharmaceuticals has a consensus price target of $5.00, suggesting a potential upside of 292.16%. Given PMV Pharmaceuticals' higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than ALX Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ALX Oncology	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, ALX Oncology's average media sentiment score of 0.00 equaled PMV Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ALX Oncology	Neutral
PMV Pharmaceuticals	Neutral

PMV Pharmaceuticals' return on equity of -68.98% beat ALX Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ALX Oncology	N/A	-124.06%	-85.57%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

98.0% of ALX Oncology shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 21.0% of ALX Oncology shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ALX Oncology has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

ALX Oncology is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ALX Oncology	N/A	N/A	-$101.69M	-$1.49	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

Summary

PMV Pharmaceuticals beats ALX Oncology on 7 of the 10 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to Entrada Therapeutics?

PMV Pharmaceuticals (NASDAQ:PMVP) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Entrada Therapeutics had 5 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 5 mentions for Entrada Therapeutics and 0 mentions for PMV Pharmaceuticals. Entrada Therapeutics' average media sentiment score of 0.02 beat PMV Pharmaceuticals' score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
PMV Pharmaceuticals	Neutral
Entrada Therapeutics	Neutral

PMV Pharmaceuticals currently has a consensus target price of $5.00, indicating a potential upside of 292.16%. Entrada Therapeutics has a consensus target price of $18.25, indicating a potential upside of 188.54%. Given PMV Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe PMV Pharmaceuticals is more favorable than Entrada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Entrada Therapeutics	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

PMV Pharmaceuticals has higher earnings, but lower revenue than Entrada Therapeutics. Entrada Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A
Entrada Therapeutics	$25.42M	9.66	-$143.75M	-$3.99	N/A

PMV Pharmaceuticals has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -2,895.05%. Entrada Therapeutics' return on equity of -51.22% beat PMV Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PMV Pharmaceuticals	N/A	-68.98%	-62.70%
Entrada Therapeutics	-2,895.05%	-51.22%	-42.20%

PMV Pharmaceuticals has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, Entrada Therapeutics has a beta of -0.09, suggesting that its stock price is 109% less volatile than the broader market.

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by insiders. Comparatively, 9.5% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

PMV Pharmaceuticals beats Entrada Therapeutics on 8 of the 15 factors compared between the two stocks.

How does PMV Pharmaceuticals compare to MacroGenics?

MacroGenics (NASDAQ:MGNX) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

MacroGenics has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, PMV Pharmaceuticals has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market.

MacroGenics has higher revenue and earnings than PMV Pharmaceuticals. MacroGenics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MacroGenics	$149.50M	1.82	-$74.62M	-$1.10	N/A
PMV Pharmaceuticals	N/A	N/A	-$77.74M	-$1.49	N/A

In the previous week, MacroGenics had 5 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 5 mentions for MacroGenics and 0 mentions for PMV Pharmaceuticals. MacroGenics' average media sentiment score of 0.20 beat PMV Pharmaceuticals' score of 0.00 indicating that MacroGenics is being referred to more favorably in the media.

Company	Overall Sentiment
MacroGenics	Neutral
PMV Pharmaceuticals	Neutral

PMV Pharmaceuticals has a net margin of 0.00% compared to MacroGenics' net margin of -44.79%. PMV Pharmaceuticals' return on equity of -68.98% beat MacroGenics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MacroGenics	-44.79%	-147.80%	-28.40%
PMV Pharmaceuticals	N/A	-68.98%	-62.70%

96.9% of MacroGenics shares are held by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are held by institutional investors. 13.6% of MacroGenics shares are held by company insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MacroGenics currently has a consensus target price of $5.50, indicating a potential upside of 28.53%. PMV Pharmaceuticals has a consensus target price of $5.00, indicating a potential upside of 292.16%. Given PMV Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe PMV Pharmaceuticals is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29
PMV Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

MacroGenics beats PMV Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get PMV Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PMVP vs. The Competition

Export

Metric	PMV Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$68.00M	$3.02B	$6.33B	$12.27B
Dividend Yield	N/A	1.97%	2.80%	5.36%
P/E Ratio	-0.86	17.75	20.91	25.45
Price / Sales	N/A	253.19	520.52	73.05
Price / Cash	N/A	56.99	43.18	55.00
Price / Book	0.77	4.58	10.00	7.01
Net Income	-$77.74M	$74.99M	$3.54B	$335.03M
7 Day Performance	-4.14%	-2.61%	0.38%	-0.43%
1 Month Performance	-12.67%	-4.25%	-0.04%	0.99%
1 Year Performance	41.45%	36.51%	34.86%	34.43%

PMV Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PMVP PMV Pharmaceuticals	2.6132 of 5 stars	$1.28 -2.7%	$5.00 +292.2%	+40.7%	$68.00M	N/A	N/A	50
PRLD Prelude Therapeutics	4.4392 of 5 stars	$4.47 -4.1%	$7.67 +71.5%	+358.2%	$281.62M	$16.72M	N/A	120	Gap Down
EDIT Editas Medicine	3.4716 of 5 stars	$2.85 -1.7%	$5.40 +89.5%	+58.5%	$279.03M	$38.69M	N/A	230
ALXO ALX Oncology	3.0348 of 5 stars	$2.04 +0.5%	$4.60 +125.5%	+364.1%	$274.50M	N/A	N/A	40
TRDA Entrada Therapeutics	3.639 of 5 stars	$6.83 -6.7%	$18.25 +167.2%	-26.7%	$265.14M	$25.42M	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PMVP) was last updated on 5/21/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. PRLD, EDIT, ALXO, TRDA, and MGNX

How does PMV Pharmaceuticals compare to Prelude Therapeutics?

Summary

How does PMV Pharmaceuticals compare to Editas Medicine?

Summary

How does PMV Pharmaceuticals compare to ALX Oncology?

Summary

How does PMV Pharmaceuticals compare to Entrada Therapeutics?

Summary

How does PMV Pharmaceuticals compare to MacroGenics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PMV Pharmaceuticals (PMVP) Competitors

PMVP vs. PRLD, EDIT, ALXO, TRDA, and MGNX

How does PMV Pharmaceuticals compare to Prelude Therapeutics?

Does the media refer more to PMVP or PRLD?

Do insiders & institutionals believe in PMVP or PRLD?

Which has better valuation and earnings, PMVP or PRLD?

Which has more volatility & risk, PMVP or PRLD?

Is PMVP or PRLD more profitable?

Do analysts rate PMVP or PRLD?

Summary

How does PMV Pharmaceuticals compare to Editas Medicine?

Which has more volatility and risk, EDIT or PMVP?

Do insiders and institutionals hold more shares of EDIT or PMVP?

Which has higher valuation and earnings, EDIT or PMVP?

Do analysts recommend EDIT or PMVP?

Is EDIT or PMVP more profitable?

Does the media prefer EDIT or PMVP?

Summary

How does PMV Pharmaceuticals compare to ALX Oncology?

Do analysts prefer ALXO or PMVP?

Does the media favor ALXO or PMVP?

Is ALXO or PMVP more profitable?

Do institutionals and insiders have more ownership in ALXO or PMVP?

Which has more volatility and risk, ALXO or PMVP?

Which has better valuation & earnings, ALXO or PMVP?

Summary

How does PMV Pharmaceuticals compare to Entrada Therapeutics?

Does the media refer more to PMVP or TRDA?

Do analysts prefer PMVP or TRDA?

Which has preferable earnings & valuation, PMVP or TRDA?

Is PMVP or TRDA more profitable?

Which has more risk and volatility, PMVP or TRDA?

Do institutionals & insiders hold more shares of PMVP or TRDA?

Summary

How does PMV Pharmaceuticals compare to MacroGenics?

Which has more volatility and risk, MGNX or PMVP?

Which has preferable valuation and earnings, MGNX or PMVP?

Does the media prefer MGNX or PMVP?

Is MGNX or PMVP more profitable?

Do institutionals and insiders have more ownership in MGNX or PMVP?

Do analysts recommend MGNX or PMVP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMVP vs. The Competition

PMV Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools